Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19

Affiliations

• ¹ Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China.
• ² Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
• ³ Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
• ⁴ Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
• ⁵ Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, China.
• ⁶ Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China.
• ⁷ Trauma Center, Peking University People's Hospital, Beijing, 100044, China.
• ⁸ Beijing Haidian Hospital, Haidian Section of Peking University Third Hospital, Beijing, 100080, China.
• ⁹ Department of Cardiology, Peking University Third Hospital, Beijing, 100191, China.
• ¹⁰ Institute of Medical Innovation, Peking University Third Hospital, Beijing, 100191, China.
• ¹¹ Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China. liudongyang@vip.sina.com.
• ¹² Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, China. shenning1972@126.com.